期刊文献+

阿尔茨海默病患者血小板脂质筏内胆固醇含量的变化 被引量:1

原文传递
导出
摘要 阿尔茨海默病(Alzheimer's disease,AD)是老年痴呆最常见的一种类型.随着人口老龄化的加速,AD的患病率呈现上升趋势,给社会及家庭带来沉重的负担.近年来,有关AD的治疗研究略有成效,研发出了一些相对有效的治疗药物,可暂时缓解AD的快速进展.但晚期疗效较差,因此AD的早期诊断及治疗十分关键,寻找能帮助临床诊断的生化指标具有很大的意义[1-2].β淀粉样蛋白(Aβ)作为老年斑的主要成分,其在脑组织中的大量沉积被认为是AD病理机制的核心所在,是AD发病的关键环节.脂质筏为膜脂双层内含有特殊脂质和蛋白的微区,富含胆固醇和鞘脂[3-4].越来越多的研究显示脂质筏在AD的病理发生及发展过程中发挥重要作用,参与Aβ致AD发病的全过程[5].但目前AD患者外周血小板脂质筏内胆固醇含量有无异常尚未见相关报道.本研究的主要目的是检测血小板脂质筏内胆固醇含量,探讨其在AD诊断中的潜在价值.
出处 《中华神经科杂志》 CAS CSCD 北大核心 2014年第3期185-188,共4页 Chinese Journal of Neurology
  • 相关文献

参考文献29

  • 1贾建平,唐毅,王芬.重视阿尔茨海默病的痴呆前阶段[J].中华神经科杂志,2013,46(1):2-4. 被引量:18
  • 2晏勇.重视阿尔茨海默病的早期诊断[J].中华神经科杂志,2012,45(2):73-75. 被引量:6
  • 3Pike LJ. Rafts defined: a report on the Keystone Symposium onLipid Rafts and Cell Function[J] . J Lipid Res, 2006,47 ; 1597-1598.
  • 4Rushworth JV, Hooper NM. Lipid Rafts: Linking Alzheimer * sAmyloid-p Production, Aggregation, and Toxicity at NeuronalMembranes[J]. Int J Alzheimers Dis, 2011, 2011 : 603052.
  • 5Colciaghi F,Marcelo E, Borroni B, et al. Platelet APP, ADAM10 and BACE alternations in early stages of Alzheimer disease[J]. Neurology, 2004, 62: 498-501.
  • 6Shrimpton CN,Gousset K,Tablin,et al. Isolation and analysis ofplatelet lipid rafts[J]. Methods Mol Biol, 2004, 273 : 213-228.
  • 7Thinakaran G, Koo EH. Amyloid precursor protein trafficking,processing, and function[J]. J Biol Chem, 2008,283 : 29615-29619.
  • 8杨红旗,冯淑曼,蒋秋焕,马建军.轻度认知功能障碍和阿尔茨海默病患者血小板α和β分泌酶活性的变化[J].中华神经科杂志,2012,45(11):783-786. 被引量:4
  • 9Borroni B, Agosti C, Marcello E, et al. Blood cell markers inAlzheimer disease : amyloid Precursor Protein form ratio inplatelets[J]. Exp Gerontol, 2010, 45 : 53-56.
  • 10Shi C,Liu J, Wu F, et al. p-sitosterol inhibits high cholesterol-induced platelet p-amyloid release [J]. J Bioenerg Biomembr,2011, 43; 691-697.

二级参考文献43

  • 1杨红旗,陈生弟.α分泌酶在阿尔茨海默病治疗中的作用[J].生物化学与生物物理进展,2006,33(2):109-115. 被引量:18
  • 2黄小钦,贾建平,樊春秋,董秀敏.阿尔茨海默病患者血小板淀粉样前体蛋白代谢的改变[J].中华神经科杂志,2007,40(6):373-375. 被引量:1
  • 3Leung KK, Shen KK, Barnes J, et al. Increasing power to predict mild cognitive impairment conversion to Alzheimer' s disease using hippocampal atrophy rate and statistical shape models. Med Image Comput Comput Assist Interv, 2010,13 : 125-132.
  • 4Zetzsche T, Rujescu D, Hardy J, et al. Advances and perspectives from genetic research: development of biological markers in Alzheimer' s disease. Expert Rev Mol Diagn, 2010, 10 : 667 -690.
  • 5Colciaghi F, Marcello E, Borroni B, et al. Platelet APP, ADAM 10 and BACE alternations in early stages of Alzheimer disease. Neurology, 2004, 62: 495-501.
  • 6Tyler SJ, Dawbarn D, Wilcock GK, et al. alpha- and beta- secretase: profound changes in Alzheimer' s disease. Biochem Biophys Res Commun, 2002,299:373-376.
  • 7Colciaghi F, Borroni B, Pastorino L, et al. ot-secretase ADAMIO as well as aAPPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med, 2002,8: 67-74.
  • 8Rodrigue KM, Kennedy KM, Devous MD Sr, et al. β-Amy/oid burden in healthy aging: regional distribution and cognitive consequences. Neurology, 2012,78:387-395.
  • 9Vlassenko AG, Mintun MA, Xiong C, et al. Amyloid-beta plaque growth in cognitively normal adults : longitudinal [ 11C ] Pittsburgh compound B data. Ann Neurol, 2011,70:857-861.
  • 10Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol, 2011,69:181-192.

共引文献25

同被引文献15

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部